Sanofi rises as analysts eye results from smoker's lung drug trial
- Shares close mixed, Nvidia's 3% rise offsets debt ceiling jitters
- Nvidia surges past $1 trillion valuation amid boom in AI interest
- Analysts rush to raise Broadcom (AVGO) numbers on strong chip orders; Shares gain
- Cathie Wood says Nvidia too expensive, Tesla to benefit from AI boom
- Jet used by Tesla CEO Elon Musk lands in China - Reuters
Get Alerts SASY Hot Sheet
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 3 | New: 43
Join SI Premium – FREE
By Scott Kanowsky
Investing.com -- Shares in Sanofi SA (EPA: SASY) climbed by more than 5%, as analysts noted the "blockbuster potential" of the French drugmaker's asthma and eczema medicine Dupixent after results from a Phase 3 trial showed it met all targets in treating so-called "smoker's lung."
Sanofi said Dupixent, which it developed in conjunction with U.S. biotech firm Regeneron Pharmaceuticals (NASDAQ: REGN), showed a "clinically meaningful and highly significant" reduction in moderate or severe cases of chronic obstructive pulmonary disease (COPD), an ailment that can cause airflow blockage and breathing-related problems.
In a joint statement, Sanofi and Regeneron credited a "bold" decision to bring Dupixent to Phase 3 testing for shaving off years of standard clinical development.
"These results also validate the role type 2 inflammation plays in driving COPD in these patients, advancing the scientific community’s understanding of the underlying biology of this disease," said Regeneron president and chief scientific officer George Yancopoulos.
According to the companies, the trial saw a randomized group 939 adults who were current or former smokers aged 40 to 80 years old receive either Dupixent or a placebo. Those patients who took Dupixent saw a 30% fall in COPD exacerbations over a 52-week period, as well as improved lung function.
Analysts at Jefferies called the readout from the trial "impressive," adding that it sets the stage for Dupixent to be the first biologic drug with a "substantial market opportunity." Earnings per share estimates, the Jefferies analysts said, should see continued upgrades in the wake of the trial.
You May Also Be Interested In
- Netflix (NFLX) shares have more upside, say Jefferies equity analysts
- Ambarella (AMBA) Tops Q1 EPS by 5c; Guides Q2 Revenues Below the Street
- Sportsmans Warehouse (SPWH) Misses Q1 EPS by 42c; Offers Guidance
Create E-mail Alert Related CategoriesAnalyst Comments, Hot FDA News, Hot List, Investing
Related EntitiesJefferies & Co, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!